Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ:MDGL
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-3.78Last Year’s EPS
-7.38Same Quarter Last Year
Strong Buy
Based on 15 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: 4.37%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
Madrigal Pharmaceuticals demonstrated strong performance with the successful launch of Rezdiffra, significant prescriber engagement, and promising clinical data. Despite rising expenses and market challenges, the company's financial health and strategic positioning remain robust.Company Guidance
During the Madrigal Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Conference Call, significant metrics were highlighted, showcasing the company's robust performance and strategic progress. The U.S. launch of Rezdiffra was a focal point, with net sales reaching $103 million in Q4 2024, marking a 66% quarter-over-quarter growth, and total net sales of $180 million for the year, despite launching in April. The drug achieved over 80% commercial coverage a quarter ahead of schedule, with more than 11,800 patients on therapy by year-end. The company's prescriber base saw substantial engagement, with approximately 60% of the top 6,000 target prescribers having prescribed Rezdiffra by Q4. The call also discussed the promising two-year data from the Phase 3 MAESTRO-NAFLD trial's open-label arm, which showed a mean 6.7 kPa reduction in liver stiffness among F4c patients, adding confidence to ongoing clinical trials and the potential expansion of Rezdiffra's market. Looking ahead, Madrigal is preparing for Rezdiffra's European regulatory decision and potential market expansion into compensated MASH cirrhosis, with the MAESTRO-NASH outcomes trial data expected in 2027.Successful Launch of Rezdiffra
Madrigal Pharmaceuticals achieved $103 million in net sales in Q4 2024, marking a 66% quarter-over-quarter growth. For the full year, the company generated $180 million in net sales, despite launching only in April.
Significant Prescriber Engagement
By the fourth quarter, approximately 60% of the top 6,000 target prescribers had prescribed Rezdiffra, up from 40% in the third quarter. Overall, 40% of the total 14,000 target prescribers had prescribed the drug by year-end.
Promising Data for Compensated MASH Cirrhosis
Two-year data from the Phase 3 MAESTRO-NAFLD trial showed a mean 6.7 kPa reduction in liver stiffness among F4c MASH patients, which is associated with a decreased risk of liver-related clinical events.
Strong Financial Position
Madrigal ended 2024 with $931.3 million in cash, cash equivalents, restricted cash, and marketable securities, positioning the company well to support ongoing and planned launches.
---
MDGL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MDGL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $309.49 | $355.88 | +14.99% |
| Oct 31, 2024 | $215.93 | $259.34 | +20.10% |
| Aug 07, 2024 | $266.56 | $234.08 | -12.18% |
| May 07, 2024 | $235.57 | $217.96 | -7.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Madrigal Pharmaceuticals Inc (MDGL) report earnings?
Madrigal Pharmaceuticals Inc (MDGL) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Madrigal Pharmaceuticals Inc (MDGL) earnings time?
Madrigal Pharmaceuticals Inc (MDGL) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MDGL EPS forecast?
MDGL EPS forecast for the fiscal quarter 2025 (Q1) is -3.78.
---